225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide-labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical sit...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 7, 2016
|
| In: |
Journal of nuclear medicine
Year: 2016, Jahrgang: 57, Heft: 12, Pages: 1941-1944 |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.116.178673 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.2967/jnumed.116.178673 Verlag, kostenfrei, Volltext: http://jnm.snmjournals.org/content/57/12/1941 
|
| Verfasserangaben: | Clemens Kratochwil, Frank Bruchertseifer, Frederik L. Giesel, Mirjam Weis, Frederik A. Verburg, Felix Mottaghy, Klaus Kopka, Christos Apostolidis, Uwe Haberkorn, and Alfred Morgenstern |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1565078861 | ||
| 003 | DE-627 | ||
| 005 | 20230427142106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171107s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2967/jnumed.116.178673 |2 doi | |
| 035 | |a (DE-627)1565078861 | ||
| 035 | |a (DE-576)495078867 | ||
| 035 | |a (DE-599)BSZ495078867 | ||
| 035 | |a (OCoLC)1340981676 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kratochwil, Clemens |d 1978- |e VerfasserIn |0 (DE-588)134026276 |0 (DE-627)559871686 |0 (DE-576)300262787 |4 aut | |
| 245 | 1 | 0 | |a 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer |c Clemens Kratochwil, Frank Bruchertseifer, Frederik L. Giesel, Mirjam Weis, Frederik A. Verburg, Felix Mottaghy, Klaus Kopka, Christos Apostolidis, Uwe Haberkorn, and Alfred Morgenstern |
| 264 | 1 | |c July 7, 2016 | |
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 07.11.2017 | ||
| 520 | |a Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide-labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical situations who showed a complete response to 225Ac-PSMA-617 therapy. Methods: 68Ga-PSMA-11 PET/CT validated the presence of the PSMA-positive tumor phenotype. A 100-kBq activity of 225Ac-PSMA-617 per kilogram of body weight was administered bimonthly. Prostate-specific antigen response and hematologic toxicity were measured at least every 4 wk. Restaging was performed with 68Ga-PSMA-11 PET/CT. Results: Both patients experienced a prostate-specific antigen decline to below the measurable level and showed a complete response on imaging. No relevant hematologic toxicity was observed. Xerostomia was the only mentionable clinical side effect. Conclusion: Targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancer patients. | ||
| 650 | 4 | |a 225Ac | |
| 650 | 4 | |a alpha-therapy | |
| 650 | 4 | |a PSMA | |
| 700 | 1 | |a Giesel, Frederik L. |d 1970- |e VerfasserIn |0 (DE-588)129031240 |0 (DE-627)387883878 |0 (DE-576)297457071 |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nuclear medicine |d New York, NY : Soc., 1964 |g 57(2016), 12, Seite 1941-1944 |h Online-Ressource |w (DE-627)325793603 |w (DE-600)2040222-3 |w (DE-576)09475277X |x 2159-662X |7 nnas |a 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer |
| 773 | 1 | 8 | |g volume:57 |g year:2016 |g number:12 |g pages:1941-1944 |g extent:4 |a 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2967/jnumed.116.178673 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://jnm.snmjournals.org/content/57/12/1941 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171107 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 9 | ||
| 998 | |g 129031240 |a Giesel, Frederik L. |m 129031240:Giesel, Frederik L. |d 910000 |d 911400 |e 910000PG129031240 |e 911400PG129031240 |k 0/910000/ |k 1/910000/911400/ |p 3 | ||
| 998 | |g 134026276 |a Kratochwil, Clemens |m 134026276:Kratochwil, Clemens |d 910000 |d 911400 |e 910000PK134026276 |e 911400PK134026276 |k 0/910000/ |k 1/910000/911400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1565078861 |e 2986681018 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"4 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.2967/jnumed.116.178673"],"eki":["1565078861"]},"relHost":[{"disp":"225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancerJournal of nuclear medicine","recId":"325793603","language":["eng"],"titleAlt":[{"title":"JNM"}],"pubHistory":["Nachgewiesen 5.1964 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"name":{"displayForm":["Society of Nuclear Medicine"]},"origin":[{"publisherPlace":"New York, NY","dateIssuedKey":"1964","dateIssuedDisp":"1964-","publisher":"Soc."}],"corporate":[{"role":"isb","display":"Society of Nuclear Medicine"}],"title":[{"title":"Journal of nuclear medicine","subtitle":"JNM","title_sort":"Journal of nuclear medicine"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["325793603"],"zdb":["2040222-3"],"issn":["2159-662X","1535-5667"]},"part":{"volume":"57","text":"57(2016), 12, Seite 1941-1944","year":"2016","pages":"1941-1944","extent":"4","issue":"12"},"note":["Gesehen am 13.12.2021"]}],"note":["Gesehen am 07.11.2017"],"person":[{"role":"aut","family":"Kratochwil","given":"Clemens","display":"Kratochwil, Clemens"},{"display":"Giesel, Frederik L.","given":"Frederik L.","family":"Giesel","role":"aut"},{"family":"Haberkorn","display":"Haberkorn, Uwe","given":"Uwe","role":"aut"}],"recId":"1565078861","name":{"displayForm":["Clemens Kratochwil, Frank Bruchertseifer, Frederik L. Giesel, Mirjam Weis, Frederik A. Verburg, Felix Mottaghy, Klaus Kopka, Christos Apostolidis, Uwe Haberkorn, and Alfred Morgenstern"]},"origin":[{"dateIssuedDisp":"July 7, 2016","dateIssuedKey":"2016"}],"language":["eng"],"title":[{"title_sort":"225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer","title":"225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer"}]} | ||
| SRT | |a KRATOCHWIL225ACPSMA67201 | ||